PubMed COVID-19 Clinical Care
371 - 380 of 1290 results found
Humoral immunogenicity assessment after receiving three types of SARS-CoV-2 vaccine
Description
Several vaccines have been developed against SARS-CoV-2 and subsequently approved by national/international regulators. Detecting specific antibodies after vaccination enables us to evaluate the vaccine's effectiveness. We conducted a prospective
Hematuria in patients with IgA nephropathy after vaccine for SARS-CoV-2
Description
No abstract
How long elective surgery should be delayed from COVID-19 infection in pediatric patients?
Description
No abstract
How mutual aid proliferation developed solidarity and sense of collective responsibility in the early months of COVID-19
Description
Although mutual aid organizing is a social movement practice long sustained by queer/trans people, immigrants, people of color, and disability communities, among other communities pushed to the margins of society, with the emergence of the COVID-19
Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial
Description
CONCLUSIONS AND RELEVANCE: Among outpatients with mild to moderate COVID-19, treatment with fluvoxamine does not reduce duration of COVID-19 symptoms.
Humoral response against spike protein enhanced by fifth and sixth COVID-19 mRNA vaccine in the uninfected and infected subjects
Description
Antibody obtained by the coronavirus disease-19 (COVID-19) mRNA vaccine declines over time, and additional vaccinations are offered. It is not clear how repeated vaccination affects humoral immunity in uninfected individuals. We analyzed
Hemophagocytic lymphohistiocytosis (HLH) after COVID-19 vaccination
Description
No abstract
Human monoclonal antibody F61 nasal spray effectively protected high-risk populations from SARS-CoV-2 variants during the COVID-19 pandemic from late 2022 to early 2023 in China
Description
Following the national dynamic zero-COVID strategy adjustment, the utilization of broad-spectrum nasal neutralizing antibodies may offer alternative approach to controlling the outbreak of Omicron variants between late 2022 and early 2023 in China